Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF is the Company's primary asset. Management believes that MANF has broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (Programmed Cell Death) in response to injury or disease. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF in the right areas and at the right time. In so doing, we are not fundamentally changing what the body does; instead, we are helping the body do what it does better to overcome injury or disease. This approach appears to be in the mainstream of thought leadership both in academia and industry, and Amarantus is positioning itself to be a leader in the field.
Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF. The Company's portfolio covering the MANF protein, gene and use as a cell therapy adjuvant is extensive and robust. We are initially focusing on the development of MANF-based protein therapeutics. In order to improve our portfolio, we are continually enhancing our IP position through the filing of additional patents, in-licensing, and acquisition of related and complementary intellectual property. These endeavours have positioned the Company for long-term success by cornering the MANF-related market and forcing future potential partners or acquirers to deal solely with Amarantus in order to get access to MANF. We will continue to prosecute this strategy to the best of our ability.
The Company has implemented a strategy centered on developing MANF in areas where partnerships with not-for-profit organizations and granting agencies are readily available. These partnerships have garnered support for Amarantus
|SOURCE Amarantus BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved